OTT-166 by OcuTerra Therapeutics for Diabetic Macular Edema: Likelihood of Approval
OTT-166 is under clinical development by OcuTerra Therapeutics and currently in Phase II for Diabetic Macular Edema.
Source: pharmaceutical-technology.com
Page 7 - Pharmaceutical Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharmaceutical Intelligence Today - Breaking & Trending Today
DVX-201 by Coeptis Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval
DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
Source: pharmaceutical-technology.com
(IO-102 + IO-103) by IO Biotech for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
(IO-102 + IO-103) is under clinical development by IO Biotech and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
Source: pharmaceutical-technology.com
Selinexor by Karyopharm Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.
Source: pharmaceutical-technology.com
Litifilimab by Biogen for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval
Litifilimab is under clinical development by Biogen and currently in Phase III for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
Source: pharmaceutical-technology.com